Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

This study has been terminated.
(Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.)
Information provided by:
Mirati Therapeutics Inc. Identifier:
First received: August 3, 2007
Last updated: January 6, 2015
Last verified: January 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2009
  Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)